The Safety and Efficacy of Recombinant Human Neuregulin-1 in Patients with Stable Chronic Heart Failure

2009 ◽  
Vol 18 ◽  
pp. S192
Author(s):  
A. Jabbour ◽  
C.S. Hayward ◽  
A.M. Keogh ◽  
E. Kotlyar ◽  
J. McCrohon ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Safety And Efficacy ◽  
Neuregulin 1

Myocardial Expression of Neuregulin-1 and Its Receptor ErbB4 in Patients with Chronic Heart Failure

2016 ◽  
Vol 64 (S 01) ◽  
Author(s):  
A. Beiras-Fernandez ◽  
J. Rothkopf ◽  
S. Kreth ◽  
A. Kornberger ◽  
U. Stock ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Neuregulin 1

Safety and efficacy of an orally active selective endothelin—A receptor antagonist in moderate-severe human chronic heart failure

1999 ◽  
Vol 5 (3) ◽  
pp. 48
Author(s):  
Horng H. Chen ◽  
Lisa M. Salz ◽  
Linda J. McKinley ◽  
Lyle J. Olson ◽  
Daniel D. Borgeson ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Receptor Antagonist ◽  
Safety And Efficacy ◽  
Endothelin A Receptor ◽  
Endothelin A ◽  
Orally Active

Recombinant Human Neuregulin-1 (rhNRG-1) Improves Cardiac Output in Patients with Stable Chronic Heart Failure

2007 ◽  
Vol 16 ◽  
pp. S13
Author(s):  
A. Jabbour ◽  
C. Hayward ◽  
A. Keogh ◽  
E. Kotlyar ◽  
X. Liu ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiac Output ◽  
Chronic Heart Failure ◽  
Neuregulin 1

scholarly journals Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses

2011 ◽  
Vol 13 (1) ◽  
pp. 83-92 ◽  
Author(s):  
Andrew Jabbour ◽  
Christopher S. Hayward ◽  
Anne M. Keogh ◽  
Eugene Kotlyar ◽  
Jane A. McCrohon ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Parenteral Administration ◽  
Neuregulin 1

scholarly journals Circulating Neuregulin-1 and Chronic Heart Failure with Preserved Ejection

Kardiologiia ◽  
2020 ◽  
Vol 60 (11) ◽  
pp. 128-136
Author(s):  
A. A. Shchendrigina ◽  
K. A. Zhbanov ◽  
E. V. Privalova ◽  
A. O. Iusupova ◽  
A. H. Bytdaeva ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Left Ventricular ◽  
Reverse Remodeling ◽  
Neuregulin 1 ◽  
Early Markers ◽  
Erbb Receptor Family ◽  
Socially Relevant ◽  
Paracrine Growth Factor ◽  
High Level

Chronic heart failure (CHF) with preserved ejection fraction (CHFpEF) is an unsolved, socially relevant challenge since it is associated with a high level of morbidity and mortality. Early markers for this pathology are unavailable, and therapeutic approaches are undeveloped. This necessitates extensive studying the mechanisms of CHFpEF to identify therapeutic targets. According to current notions, systemic inflammation and endothelial dysfunction play an important role in the pathogenesis of CHFpEF. These processes induce the development of myocardial fibrosis and impairment of cardiomyocyte relaxation, thereby resulting in diastolic dysfunction and increased left ventricular (LV) filling pressure. Neuregulin-1 (NRG-1) is a paracrine growth factor and a natural agonist of ErbB receptor family synthesized in the endothelium of coronary microvessels. The NRG-1 / ErbB4 system of the heart is activated at early stages of CHFpEF to enhance the cardiomyocyte resistance to oxidative stress. Preclinical and clinical (phases II and III) studies have shown that the recombinant NRG-1 therapy results in improvement of myocardial contractility and in LV reverse remodeling. Results of recent studies suggest possible anti-inflammatory and antifibrotic effects of NRG-1, which warrants studying the activity of this system in patients with CHFpEF.

Sign in / Sign up

Export Citation Format

Share Document